SeedBlink Blog

Brainhero, a Medtech startup specializing in neurofeedback therapy for children with autism and ADHD, is returning to SeedBlink three years after raising a successful €1.35 M. With certifications and a clear mission, Brainhero aims to revolutionize pediatric therapy by making it more accessible and effective. Led by serial entrepreneur Christof Götz, the company has conducted over 35,000 therapy sessions, achieved significant clinical outcomes, and developed a scalable, technology-driven model that benefits both therapists and families.

We sat down with Christof Götz to understand more about Brainhero’s mission, how the company is shaping the future of pediatric therapy, and what’s next in their roadmap for growth.

1. Christof, first of all, welcome back to SeedBlink! Can you tell us how Brainhero has evolved since your first fundraising round in 2022?

Since 2022, Brainhero has evolved from a promising concept into a certified Class IIa medical device, now actively used in therapy centers across Germany and Austria. One breakthrough was receiving a ‚€2.5 million grant from the European Commission (EIC Accelerator), which allowed us to shift our business model from B2C to a more scalable B2B2C approach. We learned that selling directly to families wasn't viable at scale due to the physical nature of our product, so we now partner with local therapists who already have access to patient networks. That is in place since October 2024.

Today, we're working with 12 active partner clinics and expanding rapidly - we even work with a larger clinic organization with access to more than 500 affected children - we are in a test phase here to prepare a major roll-out. We've also built a therapeutic and data framework that allows us to measure individual progress and adapt neurofeedback dosage to specific needs, for example, differentiating between hyperactivity and inattention within ADHD treatment.

Internally, we've restructured the team to focus on B2B growth, worked on patenting our therapist-assisting algorithms, and discovered that public institutions like youth welfare offices (Jugendämter) can finance Brainhero-creating strong potential for systemic adoption. Most importantly, we've shown that neurofeedback only works when patients train at least 3x per week, and our solution enables that at home, at scale, and with real-world impact.

2. Access to therapy is still a big issue for families across Europe and the US, where therapy waitlists average 2.5 years. What makes Brainhero’s solution more accessible than traditional therapy models?

Traditional therapy models are limited by physical capacity: therapists, rooms, and rigid schedules. That’s where Brainhero makes a real difference. Our solution brings therapy into the homes of families, guided by professionals but conducted independently by parents and children using our certified neurofeedback system.

Instead of weekly in-person sessions, therapists only need to invest about 1.5 to 2 hours per patient per month, focusing on onboarding, guidance, and progress monitoring. This hybrid model enables each therapist to treat more patients without compromising quality.

Families can get started within days instead of waiting years. Brainhero turns therapy into something that’s accessible, flexible, and truly scalable, right where it’s needed most: at home.

3. With over 35,000 therapy sessions conducted, the clinical results are compelling. Could you walk us through the science behind Brainhero?

Brainhero uses neurofeedback therapy, a scientifically grounded method based on real-time measurement of brain activity through EEG. By visualizing this activity in playful, interactive environments, the brain learns to self-regulate, much like training a muscle.

What makes Brainhero unique is how we’ve adapted this method for home-based, high-frequency training, supported by therapists. This frequency is key: clinical studies and our real-world data show that at least three sessions per week are needed to see measurable effects.

In over 35,000 sessions, we’ve observed significant improvements in children with Autism and ADHD:

• In Autism, progress was recorded across speech & communication, sociability, and sensory awareness.
• In ADHD, improvements were particularly strong in hyperactivity and inattention, among other effects.

We’ve also built a therapeutic data framework that will help personalize training protocols. For example, children with predominant hyperactivity require different neurofeedback patterns than those with attention issues.

This ability to quantify and tailor brain training, paired with real-world usability at home, makes Brainhero a unique blend of science, accessibility, and impact.

4. Achieving Class IIa status under EU MDR is no small feat. What does this certification mean for Brainhero’s credibility and expansion opportunities?

Reaching Class IIa certification under the EU Medical Device Regulation (MDR) is a major milestone and a strong signal of quality and clinical safety. The MDR is one of the most rigorous regulatory frameworks worldwide, and successfully navigating it is a seal of excellence that few digital therapies achieve.

With this certification, Brainhero is now eligible for commercialization across nearly all European countries, with only minor language and localization adjustments. It validates our entire system from the hardware and software to data handling and clinical performance and builds trust with therapists, health insurers, and public authorities.

In short, MDR certification is a game-changer for credibility and international scale. It positions Brainhero as a serious medical solution, not just a wellness tool, ready to expand in regulated markets with confidence.

5. You’ve managed to make onboarding very efficient: 45 minutes for therapists and 20 for patients. How important is this speed in today’s overburdened healthcare systems?

In healthcare systems under immense pressure, every hour counts. That’s why we’ve built Brainhero to combine clinical depth with consumer-grade usability. It’s a complex medical solution that feels as intuitive as using an Apple product.

Therapists can get started in just 45 minutes, and families are fully onboarded in 20 minutes, without needing technical expertise. No complicated setup, no long manuals, just plug, play, and progress.

This speed isn’t just convenient, it’s strategic. It removes barriers to adoption, enables fast scaling, and lets therapists treat more patients with less effort. In systems with long waitlists and limited staff, efficiency like this can be the difference between delay and access.

6. The market for neurological disorders is projected to reach nearly $150B by 2030. What’s your strategy for capturing market share in such a competitive space?

We’re starting with the most complex and underserved segment: children with Autism Spectrum Disorder. It’s a field where access is extremely limited, overlap with other diagnoses is high, and the need for structured, home-based therapy is urgent. That focus gives us a strong foundation: clinically, commercially, and technologically.

After launch, we expanded into ADHD treatment for children, and we’re now preparing to extend to adult ADHD and more severe forms of autism, including use in social care facilities. Long-term, our roadmap includes anxiety disorders, depression, and other neurological challenges, but always step by step, and based on the clinical evidence we generate.

We’re not claiming to solve everything with neurofeedback. But by proving our impact in targeted use cases, and scaling with trusted partners. We’re building a focused, sustainable entry into a massive market.

7. This round aims to fuel your expansion in Germany, Austria, and the UK. What are the key milestones you’re targeting with this funding?

This round is all about proving commercial scalability. Our goal is to lay the groundwork for reaching €1 million in annual recurring revenue (ARR), likely by next year. But with this funding, we aim to show that it’s no longer a question of if, but of when—a matter of execution and scale.

By the end of this year, we plan to:

• Solidify our business model with paying B2B partners
• Grow our active clinic network in Germany and Austria
• Prepare the UK market entry, including strategic partnerships and compliance groundwork

We’re building toward a larger Series A in 2026, which will finance:

• New clinical studies to expand our therapeutic claims
• The development of a next-generation EEG device, more scalable and cost-efficient
• Geographic expansion into the UK, Nordics, and additional EU markets

This round is our launchpad to move from early traction to a growth-ready, system-validated healthtech company.

8. Finally, as a founder with over 20 years of experience, what drives you personally in this mission, and why should investors join you in this next chapter of Brainhero?

As a father and founder, I’ve seen firsthand how exhausting and lonely the search for help can be when a child is struggling neurologically. Long waitlists, overwhelmed systems, and complex therapies often leave families without real options. That’s what drives me. And I see that. Daily.

With over two decades of experience managing complex projects, I’m not just here to build another digital tool. I’m here to create real, measurable change for families who are out of options. Brainhero brings advanced neuroscience into the home in a way that is accessible, scalable, and grounded in clinical reality.

I invite investors who believe in the power of aligned impact and business. Together, we can build something that not only grows but matters, turning science and empathy into a new standard of care.

Explore the opportunity on SeedBlink.